Quick Answer
Inhibikase Therapeutics, Inc. reported Shares Outstanding of 131.69 million shares for fiscal year 2025.
Inhibikase Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 131.69M | +89.9% |
| 2024 | 69.36M | +1021.2% |
| 2023 | 6.19M | +46.4% |
| 2022 | 4.22M | -83.2% |
| 2021 | 25.16M | +150.3% |
| 2020 | 10.05M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 74.81M | +902.2% | +0.4% |
| June 30, 2025 | 74.52M | +932.6% | +0.2% |
| March 31, 2025 | 74.34M | +1047.8% | +7.2% |
| December 31, 2024 | 69.36M | +1021.2% | +829.3% |
| September 30, 2024 | 7.46M | +39.2% | +3.4% |
| June 30, 2024 | 7.22M | +36.4% | +11.4% |
| March 31, 2024 | 6.48M | -79.1% | +4.7% |
| December 31, 2023 | 6.19M | +46.4% | +15.4% |
- Inhibikase Therapeutics, Inc. showed an increase of +89.9% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Inhibikase Therapeutics, Inc.’s shares outstanding has grown by 1210.2% (from 10.05 million shares to 131.69 million shares).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: